



## 1H FY22 Trading Update

Stephen Tomisich  
CEO and Managing Director  
24th February 2022

Science that benefits people





**Respect**



**Integrity**



**Discipline**



**Empowerment**

**Through our values and actions, we aim to  
impact human wellbeing in a meaningful way.**



**Science that benefits people**



# 1H FY22 Highlights

Science that benefits people

## Underlying revenue growth, EBITDA in line with plan

**\$43.7M**

Total  
Revenue

**20.6%<sup>1</sup>**

Revenue  
Growth

**\$4.8M**

Normalised  
EBITDA

**2.1 %**

Gross Profit  
Margin  
Expansion<sup>2</sup>

- Both business segments contributed growth.
- Organic growth of 12.8% on a constant currency basis.
- Normalised 1H FY22 EBITDA in line with expectation.
- Gross margin improvement driven by scale and efficiency benefits.


1. Constant currency basis over PCP.

2. Over PCP.



# Full Year FY22 Forecast Guidance

Science that benefits people



- Organic growth forecast at high single digit rate in 2H FY22.
- Contributions from acquisitions to step up in 2H FY22.
- Forecasting relatively broad revenue and normalised EBITDA ranges driven by the recent acquisitions and emerging technology sales growth.





**TRAJAN**

**1H FY22 Operational Update**

**Science that benefits people**



# Strong Product and Customer Growth

Science that benefits people

- Strong growth in strategic product lines; fluidic devices, proteomics-related growth drivers in tubing, and HDX.
- Consistent growth across the product portfolio with several product lines achieving circa 50%.
- Strategic chromatography consumables growth rates remain above 10% and include septa products manufactured in Connecticut, USA.
- Revenue from top ten customers grew on average 18% on PCP.
- Revenue growth from 15 of our top 20 customers.


*\* All comparisons against PCP are on a constant currency.*





# IPO Use of Funds

Science that benefits people



IPO funds have been used to:

- Support Trajan's growth strategy (strategic acquisitions and investments).
- Accelerate investment in manufacturing infrastructure (Project Neptune) –refer slide 15.
- Accelerate commercialisation of new products and technologies – refer slides 9 and 11.
- Capital raising costs and IPO related costs - \$7.1m.

**We remain active with \$33.1M cash position.**



# Execution of M&A Strategy

Science that benefits people

## From the individual to analytical information

Added capability, platforms and customer sets to our laboratory automation business (November 2021).



Created a leadership position in blood microsampling (December 2021).



Invested in consumer health monitoring (November 2021).



Completed acquisition of LEAP PAL Parts and Consumables (December 2021).






# Commercial Acceleration

- Following the MyHealthTest acquisition (March 2021), we've invested in 1H to rapidly build and resource an analytical laboratory in Melbourne, forming the basis of Trajan Analytical Services, "TAS".
- We are addressing the key barriers to broad adoption of microsampling, being cost and deployment of the laboratory workflows.
- With our technology we intend to offer and/or monetise TAS.
- ISO 15189 medical laboratory accreditation expected this FY.
- Investment of \$1.0M-\$1.5M in FY22 forecast in August remains on budget, including additional resource build in Hummingbird and  $\mu$ LLE.





# Validation of Blood Sampling is Building Scientific Papers Featuring Mitra® and hemaPEN® Technologies



Now 200+ peer reviewed scientific papers published globally on Trajan microsampling technologies, 60% in the last two years.




# Microsampling Commercial Adoption


Science that benefits people

## Trajan is now leading the way

# of Mitra® and hemaPEN® Customers  
Purchasing per Year



Mitra® and hemaPEN® Customers by Industry



\$3.0M-\$5.0M revenues expected in  
FY22 and strong growth in FY23.





1H FY22 Financials

Science that benefits people



# 1H FY22 Financials

Science that benefits people


## Strong growth profile supported by successful strategic acquisitions

### Revenue (\$M) & Gross Profit<sup>1</sup> Margin%

The Group reported overall revenues for the half-year ended 31 December 2021 of \$43.7M (2020: \$37.4M), up by 16.8%.

Full year forecast revenue range of \$104.0M to \$110.0M is driven by achieving growth in the organic business (i.e., before the impact of acquisitions) plus forecast contributions from strategic acquisitions.

Gross profit margin for the half-year ended 31 December 2021 was 41.5% (2020: 39.4%). The gross profit margin over pcip was up 2.1% points, mainly driven by efficiency and scale benefits. Forecasting gross profit margin of 41.9% for the full year.




### Normalised EBITDA (\$M) & Normalised<sup>2</sup> EBITDA Margin %

The half-year ended 31 December 2021 normalised EBITDA of \$4.8M (2020: \$5.1M) is exclusive of business acquisition expenses of \$1.8M and commercialisation costs of \$0.7M. (The pcip included mark to market Forward Exchange Contract benefit of \$0.9M.)

Full year forecast normalised EBITDA range of \$12.5M to \$13.5M is driven by achieving growth in the organic business plus the net contributions from acquisitions completed in the first half.

Whilst the net EBITDA margin contribution from acquisitions in total is not immediately margin accretive, management expect EBITDA margins to grow beyond FY22 as recent acquisitions are fully integrated and the Group benefits from acquisition synergies.



1. Gross profit excludes depreciation – cost of sales and finance cost – cost of sales.

2. Normalised EBITDA FY2021 excludes PPP loan forgiveness, ongoing listed costs, IPO related expenses and share-based payment expenses. Normalised EBITDA FY2022 excludes acquisition related costs, costs to accelerate investment in manufacturing infrastructure, and costs to accelerate commercialisation of new products and technologies.

FY2022F(R): Comprises of three parts: (1) actual first half FY2022 results, (2) forecasted second half FY2022 results per Prospectus and (3) forecasted second half FY2022 results from strategic acquisitions and accelerated growth.




# 1H FY22 Segment breakdown

Science that benefits people

## Diversified product mix delivering recurring revenue and significant growth opportunities


### Analytical Products

- Reported revenue was up 12.6% on pcp and gross profit<sup>1</sup> grew by \$1.5M in the half year, up 14.0% on PCP.
- Full year forecast revenue and gross profit driven by continued growth in the organic business.



### Life Science Solutions

- Reported revenue was up 26.2% on pcp and gross profit<sup>1</sup> grew by \$1.9M in the half year, up 49.1% on PCP.
- Full year forecast revenue and gross profit driven by continued growth in the organic business plus the net contributions from the strategic acquisitions.





# Acceleration of Margin Expansion

Science that benefits people

- “Project Neptune” has commenced. Forecast FY22 EBITDA impact remains neutral.
- Additional resource added in Nov-Jan.
- Some scheduled syringe transfers to MYS delayed in 1H due to COVID, will correct in 2H.
- Total annual gross margin gains of \$2.7M+ still expected over next two years.
- Technical and operational confidence in delivering the benefits remains high.
- As referenced in August, some COVID-19 elements such as electronics supply are challenging the timelines. Mitigating overall impact through forward planning.





# Financial Outlook

Science that benefits people



- Expecting continued revenue growth across a broad range of products and customers, with full impact of acquisitions to be realised, and organic growth to remain high.
- Gross margin expansion, driven by scale and efficiency benefits, expected to continue.
- Forecast excludes any further acquisitions; however, we remain active.





 **TRAJAN**  
**Q&A**

Science that benefits people



# Disclaimer

Science that benefits people

The material in this presentation is general background information about Trajan Group Holdings Limited (Trajan) and is current at the date of the presentation, 24 February 2022. The information in the presentation is provided for information purposes only, is in summary form and does not purport to be complete. It should be read in conjunction with Trajan's other announcements to the ASX, including the FY22 Half Year Results announcement. It is not intended to be relied upon as advice to current shareholders, investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular shareholder or investor, taxation situation or needs of any particular investor. An shareholder, investor or potential investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Trajan and conduct its own investigations and analysis. No representation is made as to the accuracy, completeness or reliability of the presentation. Trajan is not obliged to, and does not represent that it will, update the presentation for future developments.

All currency figures are in Australian dollars unless otherwise stated. Totals and change calculations may not equate precisely due to rounding.

This presentation contains statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "believe", "estimate", "plan", "target", "project", "anticipate", "expect", "intend", "likely", "may", "will", "could" or "should" or similar expressions, or by discussions of strategy, plans, objectives, targets, goals, future events or intentions. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. You are cautioned not to place undue reliance on such forward-looking statements. Such forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of Trajan or any of its related entities which may cause actual results to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements.

Past performance is also not indicative of future performance and no guarantee of future returns is implied or given. Nothing contained in this presentation is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of Trajan.

By reading this presentation you agree to be bound by the limitations set out in this disclaimer. No representation or warranty, express or implied, is made as to the accuracy, reliability, completeness or fairness of the information, opinions, forecasts, reports, estimates and conclusions contained in this presentation. To the maximum extent permitted by law, neither Trajan nor any of its related entities, or their respective directors, employees or agents, nor any other person accepts liability for loss arising from the use of or reliance on information contained in this presentation or otherwise arising in connection with it, including without limitation any liability from fault of negligence.